Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries

• Patient enrollment and monitoring with PressureSafe has commenced
• In a similar study conducted at the world’s 2^nd largest HMO, PressureSafe had efficacy of 92% in detection and the incidence of pressure injuries were reduced by 50% during the study
• A skin-color agnostic decision support device, PressureSafe, uses an AI-based algorithm and infrared light to sense beneath the skin’s surface to detect biomarkers of pressure injuries
• $26.8 billion is spent each year on the prevention and treatment of pressure injuries, and pressure injuries directly result in the death of 60,000 people annually in the U.S. 

Rosh Pina, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today the start of a usability study for its lead product, PressureSafe, at San Antonio, Texas based Methodist Healthcare. The study, titled “Safety and Efficacy of the PressureSafe Device for Early Detection of Pressure Injury in People with Various Skin Tones, Including Dark Skin Tones,” has received approval from Methodist Healthcare and has commenced patient enrollment and monitoring. Methodist Healthcare is widely regarded as one of the most respected healthcare providers in its region. With a growing network of care locations including hospitals, surgery centers, ERs, and family health clinics, each year Methodist Healthcare serves 608,000 patients, including 11,000 births, and 330,000 ER visits.

PressureSafe, an innovative non-invasive medical device that uses infrared optical spectroscopy and an AI-based algorithm, is designed to effectively detect early-stage pressure injuries for all skin tones. PressureSafe is skin-color agnostic because it uses infrared light to detect biomarker changes below the skin’s surface. The decision support device is FDA listed.

Principal Investigator of the study and Director of the Professional Nursing Practice at Methodist Healthcare, Mary Lee Potter, PhD, MBA, RN, CWOCN, commented, “This is a very important study for our nurses and entire medical team, as we are continuously seeking to improve outcomes for our patients. We look forward to utilizing PressureSafe at Methodist Hospital Metropolitan and are eager to evaluate its potential to increase the accuracy of early pressure injury detection and prevention. As the device evaluates the tissues beneath the skin and digitally assesses biomarkers, the technology can objectively augment human visual inspection, and this is very interesting for us.”